T3D Therapeutics Announces Presentation of Neuroimaging Results From a Phase 2a Trial of T3D-959 in Mild to Moderate Alzheimer’s Subjects at the 20th Annual Meeting of the American Society of Experimental Therapeutics

T3D Therapeutics, Inc. today announced that FDG-PET neuroimaging data from a Phase 2a trial with T3D-959 in mild to moderate Alzheimer’s disease subjects were presented in an oral and poster presentation entitled ‘A Neurometabolic Approach to Treating Alzheimer’s Disease: Hypothesis Testing in a Phase 2a Exploratory Clinical Trial with the New Chemical Entity T3D-959’ at the 20^th Annual Meeting of the American Society of Experimental Therapeutics. <See 2018 ASENT Presentation>